This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the current treatment landscape for radiopharmaceuticals, therapies in development, and Pluvicto’s PSMAfore data presented in November at ESMO.
Ticker(s): NVS, LLY, LNTH, FUSNWho's the expert?
Institution: Self-employed
- Board certified in radiation oncology and serves as program director for the radiation oncology residency in partnership with Hahnemann University and Drexel University.
- Treats 30 patients with LAHNC who have developed SOM due to CRT or intensity-modulated radiotherapy
- Clinical interests include breast, gastrointestinal, gynecologic, thoracic, and pediatric malignancies with specialty training in Intensity Modulated Radiation Therapy (IMRT) and brachytherapy
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
